Acquisition extends ICON’s leadership in commercialisation and market access services and brings new scientific communications capabilities.
'Firecrest Through the Body' combines Firecrest’s clinical pharmacology and graphic design expertise to create a truly unique, animated view of systems inside the body.
ICON aims to address an unmet need for a well-defined, reliable endpoint that can measure the effects of antibacterial drugs on HABP patients.
Net new business awards of $468M, backlog grew to $3.5B, revenue up 14.1% YOY to $388M aand EPS was 79c.
Cynthia voted following a global industry survey conducted by vaccine industry organisation, VaccineNation. Cynthia was the only CRO representative included in the list.
Dr. Spector is an expert in clinical development and brings to ICON over 25 years of experience in managing global drug and medical device development programmes.